UroGen Pharma Ltd. (NASDAQ:URGN) Performance and Strategic Initiatives

Font: Financial Modeling Prep  • Mar 02, 2026

• UroGen Pharma Ltd. (NASDAQ:URGN) reported a quarterly loss of $0.54 per share, outperforming the Zacks Consensus Estimate.
• The company achieved $37.84 million in revenue for Q4 2025, surpassing expectations and marking significant year-over-year growth.
• Strategic initiatives include the commercial launch of ZUSDURI™, with net sales of $15.8 million in 2025, and a favorable refinancing agreement with Pharmakon Advisors.

UroGen Pharma Ltd. (NASDAQ:URGN) is a biopharmaceutical company focused on developing and commercializing innovative solutions for urological and uro-oncological diseases. The company is part of the Zacks Medical - Biomedical and Genetics industry. UroGen's key products include ZUSDURI™, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and JELMYTO®, which has shown a 7% year-over-year growth in demand.

On March 2, 2026, Oppenheimer reiterated its "Outperform" rating for UroGen Pharma, maintaining its previous grade. At the time, the stock was trading at $19.93. Despite a recent decrease of 8.06%, with the stock priced at $19.95, UroGen's performance has shown resilience. The stock has fluctuated between $18.18 and $21.69 today, with a market capitalization of approximately $933.8 million.

UroGen Pharma's Q4 2025 earnings call, provided insights into the company's financial performance. The company reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a $0.66 loss. This marks an improvement from the $0.80 per share loss reported in the same quarter last year, representing an 18.18% positive earnings surprise.

In terms of revenue, UroGen Pharma achieved $37.84 million for the quarter ending December 2025, surpassing the Zacks Consensus Estimate by 6.42%. This is a significant increase from the $24.57 million in revenue reported in the same quarter the previous year. However, the company has only exceeded consensus revenue estimates once in the last four quarters.

UroGen Pharma's strategic initiatives include the commercial launch of ZUSDURI™, with net sales of $15.8 million in 2025. The permanent J Code for ZUSDURI, effective January 1, 2026, is expected to streamline reimbursement procedures and enhance patient access. Additionally, UroGen has refinanced its existing term loan with Pharmakon Advisors, securing additional non-dilutive capital under more favorable terms.